4 big things on horizon, page-2

licensing on horizon, radar watch alert We would suggest that Imugene is on track for a good commercial outcome with regard to PAV-PRRS. The product is not subject to the September 2002 option agreements with Merial, and as a consequence it may attract a favourable deal in terms of milestone payments and royalties from any one of a number of animal health majors. And, as we understand it, Imugene's new vaccine has been attracting multiple licensing interest.
To that end, Imugene is currently working on the last of a series of additional laboratory tests of its vectors, the design of which have been worked out by both OGTR and Imugene, in order to satisfy the regulator that its adenoviral vectors are safe for 'intentional release'. If that work leads to approval for intentional release by mid-2005, we believe that Imugene could be making its way towards filing of regulatory dossiers for approval of FAV-gamma before next year is out, meaning that the product would be on track to be in commercial use by 2006.